Kikushige Yoshikane, Miyamoto Toshihiro
Department of Medicine and Biosystemic Sciences, Kyushu University Graduate School of Medicine, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Int J Hematol. 2014 Oct;100(4):335-40. doi: 10.1007/s12185-014-1651-6. Epub 2014 Aug 7.
Human malignancies develop through the multistep acquisition of critical somatic mutations during the clinical course. Regarding hematological malignancies, recent novel findings have indicated that hematopoietic stem cells (HSCs), which have the potential to self-renew and differentiate into multilineage hematopoietic cells, are an important cellular target for the accumulation of critical somatic mutations and play a central role in myeloid malignancy development. In contrast to myeloid malignancies, mature lymphoid malignancies, such as chronic lymphocytic leukemia (CLL), are considered to directly originate from differentiated mature lymphocytes; however, we previously reported that the propensity to generate clonal B cells had already been acquired at the HSC stage in CLL patients. Similarly, HSC involvement has been reported in the pathogenesis of mature T cell lymphomas. These studies indicate that, in mature lymphoid, if not all, malignancies, HSCs should be considered as the critical cellular target in the oncogenic process. The prevalence of these hematological malignancies dramatically increases with age, and the effect of aging HSCs should thus be taken into account when investigating the stepwise malignant transformation process of these age-associated malignancies.
人类恶性肿瘤是在临床病程中通过多步骤获得关键体细胞突变而发展起来的。关于血液系统恶性肿瘤,最近的新发现表明,具有自我更新和分化为多谱系造血细胞潜能的造血干细胞(HSCs)是关键体细胞突变积累的重要细胞靶点,并且在髓系恶性肿瘤的发生发展中起核心作用。与髓系恶性肿瘤不同,成熟淋巴细胞恶性肿瘤,如慢性淋巴细胞白血病(CLL),被认为直接起源于分化成熟的淋巴细胞;然而,我们之前报道过,CLL患者在造血干细胞阶段就已经获得了产生克隆性B细胞的倾向。同样,在成熟T细胞淋巴瘤的发病机制中也有造血干细胞参与的报道。这些研究表明,在成熟淋巴细胞恶性肿瘤(即便不是所有的)中,造血干细胞应被视为致癌过程中的关键细胞靶点。这些血液系统恶性肿瘤的患病率随年龄显著增加,因此在研究这些与年龄相关的恶性肿瘤的逐步恶性转化过程时,应考虑衰老造血干细胞的影响。